

Dear Author,

Here are the proofs of your article.

- You can submit your corrections **online**, via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/ corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

### Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL: [http://dx.doi.org/\[DOI\]](http://dx.doi.org/[DOI]).

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information go to: <http://www.link.springer.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us if you would like to have these documents returned.

# Metadata of the article that will be visualized in OnlineFirst

ArticleTitle	Pediatric Pharmacology of Desmopressin in Children with Enuresis: A Comprehensive Review	
Article Sub-Title		
Article CopyRight	Springer Nature Switzerland AG (This will be the copyright line in the final PDF)	
Journal Name	Pediatric Drugs	
Corresponding Author	Family Name	<b>Gasthuys</b>
	Particle	
	Given Name	<b>Elke</b>
	Suffix	
	Division	Department of Pediatric Nephrology, Faculty of Medicine and Health Sciences
	Organization	Ghent University Hospital
	Address	C. Heymanslaan 10, 9000, Ghent, Belgium
	Division	Health, Innovation and Research Institute, Faculty of Medicine and Health Sciences
	Organization	Ghent University Hospital
	Address	C. Heymanslaan 10, 9000, Ghent, Belgium
	Division	Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy
	Organization	Freie Universitaet Berlin
	Address	Kelchstr. 31, 12169, Berlin, Germany
	Division	Department of Bioanalysis, Faculty of Pharmaceutical Sciences
	Organization	Ghent University
	Address	Ottergemsesteenweg 460, 9000, Ghent, Belgium
	Phone	
	Fax	
	Email	elke.gasthuys@ugent.be
	URL	
	ORCID	<a href="http://orcid.org/0000-0002-0503-3560">http://orcid.org/0000-0002-0503-3560</a>
Author	Family Name	<b>Dossche</b>
	Particle	
	Given Name	<b>Lien</b>
	Suffix	
	Division	Department of Pediatric Nephrology, Faculty of Medicine and Health Sciences
	Organization	Ghent University Hospital
	Address	C. Heymanslaan 10, 9000, Ghent, Belgium
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

Author	Family Name	<b>Michelet</b>
	Particle	
	Given Name	<b>Robin</b>
	Suffix	
	Division	Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy
	Organization	Freie Universitaet Berlin
	Address	Kelchstr. 31, 12169, Berlin, Germany
	Phone	
	Fax	
	Email	
	URL	
	ORCID	
Author	Family Name	<b>Nørgaard</b>
	Particle	
	Given Name	<b>Jens Peter</b>
	Suffix	
	Division	Department of Pediatric Nephrology, Faculty of Medicine and Health Sciences
	Organization	Ghent University Hospital
	Address	C. Heymanslaan 10, 9000, Ghent, Belgium
	Phone	
	Fax	
	Email	
	URL	
	ORCID	
Author	Family Name	<b>Devreese</b>
	Particle	
	Given Name	<b>Mathias</b>
	Suffix	
	Division	Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine
	Organization	Ghent University
	Address	Salisburylaan 133, 9820, Merelbeke, Belgium
	Phone	
	Fax	
	Email	
	URL	
	ORCID	
Author	Family Name	<b>Croubels</b>
	Particle	
	Given Name	<b>Siska</b>
	Suffix	
	Division	Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine
	Organization	Ghent University
	Address	Salisburylaan 133, 9820, Merelbeke, Belgium

Phone  
Fax  
Email  
URL  
ORCID

---

Author	Family Name	<b>Vermeulen</b>
	Particle	
	Given Name	<b>An</b>
	Suffix	
	Division	Department of Bioanalysis, Faculty of Pharmaceutical Sciences
	Organization	Ghent University
	Address	Ottergemsesteenweg 460, 9000, Ghent, Belgium
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

---

Author	Family Name	<b>Bocxlaer</b>
	Particle	<b>Van</b>
	Given Name	<b>Jan</b>
	Suffix	
	Division	Department of Bioanalysis, Faculty of Pharmaceutical Sciences
	Organization	Ghent University
	Address	Ottergemsesteenweg 460, 9000, Ghent, Belgium
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

---

Author	Family Name	<b>Walle</b>
	Particle	
	Given Name	<b>Johan Vande</b>
	Suffix	
	Division	Department of Pediatric Nephrology, Faculty of Medicine and Health Sciences
	Organization	Ghent University Hospital
	Address	C. Heymanslaan 10, 9000, Ghent, Belgium
	Phone	
	Fax	
	Email	
	URL	
	ORCID	

---

Schedule	Received
	Revised

## Abstract

Desmopressin is a synthetic analogue of the natural antidiuretic hormone arginine vasopressin. Over the years, it has been clinically used to manage nocturnal polyuria in children with enuresis. Various pharmaceutical formulations of desmopressin have been commercialized for this indication—nasal spray, nasal drops, oral tablet and oral lyophilizate. Despite the fact that desmopressin is a frequently prescribed drug in children, its use and posology is based on limited pediatric data. This review provides an overview of the current pediatric pharmacological data related to the different desmopressin formulations, including their pharmacokinetics, pharmacodynamics and adverse events. Regarding the pharmacokinetics, a profound food effect on the oral bioavailability was demonstrated as well as different plasma concentration–time profiles (double absorption peak) of the desmopressin lyophilizate between adults and children. Literature about maturational differences in distribution, metabolism and excretion of desmopressin is rather limited. Regarding the pharmacodynamics, formulation/dose/food effect and predictors of response were evaluated. The lyophilizate is the preferred formulation, but the claimed bioequivalence in adults (200 µg tablet and 120 µg lyophilizate), could not be readily extrapolated to children. Prescribing the standard flat-dose regimen to the entire pediatric population might be insufficient to attain response to desmopressin treatment, whereby dosing schemes based on age and weight were proposed. Moreover, response to desmopressin is variable, whereby complete-, partial- and non-responders are reported. Different reasons were enumerated that might explain the difference in response rate to desmopressin observed: different pathophysiological mechanisms, bladder capacity and other predictive factors (i.e. breast feeding, familial history, compliance, sex, etc.). Also, the relapse rate of desmopressin treatment was high, rendering it necessary to use a pragmatic approach for the treatment of enuresis, whereby careful consideration of the position of desmopressin within this treatment is required. Regarding the safety of the different desmopressin formulations, the use of desmopressin was generally considered safe, but additional measures should be taken to prevent severe hyponatremia. To conclude the review, to date, major knowledge gaps in pediatric pharmacological aspects of the different desmopressin formulations still remain. Additional information should be collected about the clinical relevance of the double absorption peak, the food effect, the bioequivalence/therapeutic equivalence, the pediatric adapted dosing regimens, the study endpoints and the difference between performing studies at daytime or at nighttime. To fill in these gaps, additional well designed pharmacokinetic and pharmacodynamic studies in children should be performed.

## Footnote Information



2 **Pediatric Pharmacology of Desmopressin in Children with Enuresis:**  
3 **A Comprehensive Review**

4 **Elke Gasthuys<sup>1,2,3,4</sup> · Lien Dossche<sup>1</sup> · Robin Michelet<sup>3</sup> · Jens Peter Nørgaard<sup>1</sup> · Mathias Devreese<sup>5</sup> · Siska Croubels<sup>5</sup> ·**  
5 **An Vermeulen<sup>4</sup> · Jan Van Bocxlaer<sup>4</sup> · Johan Vande Walle<sup>1</sup>**

6  
7 © Springer Nature Switzerland AG 2020

8 **Abstract**

**AQ1** Desmopressin is a synthetic analogue of the natural antidiuretic hormone arginine vasopressin. Over the years, it has been clinically used to manage nocturnal polyuria in children with enuresis. Various pharmaceutical formulations of desmopressin have been commercialized for this indication—nasal spray, nasal drops, oral tablet and oral lyophilizate. Despite the fact that desmopressin is a frequently prescribed drug in children, its use and posology is based on limited pediatric data. This review provides an overview of the current pediatric pharmacological data related to the different desmopressin formulations, including their pharmacokinetics, pharmacodynamics and adverse events. Regarding the pharmacokinetics, a profound food effect on the oral bioavailability was demonstrated as well as different plasma concentration–time profiles (double absorption peak) of the desmopressin lyophilizate between adults and children. Literature about maturational differences in distribution, metabolism and excretion of desmopressin is rather limited. Regarding the pharmacodynamics, formulation/dose/food effect and predictors of response were evaluated. The lyophilizate is the preferred formulation, but the claimed bioequivalence in adults (200 µg tablet and 120 µg lyophilizate), could not be readily extrapolated to children. Prescribing the standard flat-dose regimen to the entire pediatric population might be insufficient to attain response to desmopressin treatment, whereby dosing schemes based on age and weight were proposed. Moreover, response to desmopressin is variable, whereby complete-, partial- and non-responders are reported. Different reasons were enumerated that might explain the difference in response rate to desmopressin observed: different pathophysiological mechanisms, bladder capacity and other predictive factors (i.e. breast feeding, familial history, compliance, sex, etc.). Also, the relapse rate of desmopressin treatment was high, rendering it necessary to use a pragmatic approach for the treatment of enuresis, whereby careful consideration of the position of desmopressin within this treatment is required. Regarding the safety of the different desmopressin formulations, the use of desmopressin was generally considered safe, but additional measures should be taken to prevent severe hyponatremia. To conclude the review, to date, major knowledge gaps in pediatric pharmacological aspects of the different desmopressin formulations still remain. Additional information should be collected about the clinical relevance of the double absorption peak, the food effect, the bioequivalence/therapeutic equivalence, the pediatric adapted dosing regimens, the study endpoints and the difference between performing studies at daytime or at nighttime. To fill in these gaps, additional well designed pharmacokinetic and pharmacodynamic studies in children should be performed.

A1 ✉ Elke Gasthuys  
A2 elke.gasthuys@ugent.be

A3 Extended author information available on the last page of the article

## Key Points

The current review summarizes the available literature concerning the pharmacology of desmopressin in children with enuresis.

Despite the fact that desmopressin has been available for more than 40 years, there remains a need for additional pharmacokinetic and pharmacodynamic studies in children.

To date, multiple research questions remain unanswered in the pediatric population: is there a double absorption peak? Is there a food effect? Is there bioequivalence/therapeutic equivalence? What is the optimal dosing regimen?

## 1 Introduction

The synthetic vasopressin analogue desmopressin has been used clinically for > 40 years in the treatment of enuresis (high, diluted urine output overnight) and central diabetes insipidus (CDI) [1–4]. In very high doses, desmopressin is also used to treat the congenital bleeding disorders, hemophilia A and von Willebrand disease, since it increases the von Willebrand factor, coagulation factor VIII and tissue plasminogen activator [5, 6]. Moreover, desmopressin has proven suitable to diagnose renal concentrating capacity (i.e. patients with CDI, urinary tract infections and suspected kidney damage) [7, 8]. The current review focusses on the use of desmopressin in children with enuresis, and does not discuss the use in diagnostic testing, nor in the treatment of children with CDI or congenital bleeding disorders.

Over the years, various pharmaceutical formulations of the antidiuretic desmopressin have been commercialized: nasal spray (since 1972), nasal drops (since 1972), oral tablet (since 1987) and oral lyophilizate (since 2005) [9]. All formulations have proven efficacy for children with enuresis, that is, resulted in a reduction of the number of wet nights. The conventional route of administration of desmopressin in adults and children used to be intranasal (IN) (drops or spray), since this route bypasses the gastrointestinal tract, leading to an increase in absolute bioavailability and hence a lower dose. However, in 2007, the Food and Drug Administration (FDA) announced a post-marketing drug safety warning about the use of nasal sprays in children, which was based on a limited number of case reports demonstrating that IN administration of desmopressin could potentially lead to severe hyponatremia and seizures [10]. These adverse


events could be attributed to the variability in absorption and unintentional overdosing when using the nasal spray [11, 12]. Consequently, the use of IN formulations is no longer approved for treating enuresis in children in the United States of America (US) and most of the European countries. The latter required a definitive switch to oral formulations, despite the limited efficacy and safety data for these formulations in the pediatric population (i.e. lack of pharmacokinetic (PK) data of oral desmopressin, lack of bioequivalence studies, lack of availability of size-dependent dosing strategies, lack of safety studies). Over the years, additional research was performed to fill in some knowledge gaps [13–17, Dossche et al., submitted], but additional research is still required. Therefore, the aim of the current review is to provide an overview of the pediatric pharmacological data of the different desmopressin formulations, including their therapeutic use, PK, pharmacodynamics (PD) and safety. This overview contributes to the identification of which information is already available and which information is still missing to enable adapted desmopressin treatment strategies for children.

## 2 Structure and Physicochemical Properties

Desmopressin (1-desamino-8-D-arginine vasopressin, dDAVP), is a synthetic analogue of the natural antidiuretic hormone arginine vasopressin (AVP). Desmopressin was first synthesized in 1967 by deamination of the cysteine residue (prolonged activity due to a lipophilic N-terminal) and replacing the L-arginine configuration with the D-arginine configuration (reduced vasopressor activity due to changes in polarization of the molecule) (Fig. 1) [18]. The molecular formula of the nonapeptide desmopressin is  $C_{46}H_{64}N_{14}O_{12}S_2$ , with a molecular mass of 1069.224 g/mol. The active ingredient of the different formulations is desmopressin acetate. Desmopressin has a negative clog P (–7.711), which demonstrates the extreme hydrophilicity of this drug [19]. Desmopressin is a base with a pKa of 11.8 (strongest base).

## 3 Mode of Action


Desmopressin is mainly designed to treat nocturnal polyuria with increased free water diuresis by acting on the  $V_2$  vasopressin receptors of the collecting ducts [20–22]. The drug binds to the  $V_2$  receptor in the basolateral membrane of the collecting duct, stimulating the  $G_s$ -coupled protein to activate adenylate cyclase, leading to the formation of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). cAMP binds to protein kinase A, activating the phosphorylation cascade,



**Fig. 1** Chemical structure of vasopressin (left, **a**) and desmopressin (right, **b**). Deamination (green) and L-arginine versus D-arginine configuration (*orange*) (made in Chemdraw 16®, PerkinElmer, USA)



114 whereby the exocytosis of aquaporin-2 water channels  
 115 from cytoplasmic aquaporin-2 water channel-containing  
 116 vesicles towards the apical membrane of the collecting  
 117 ducts is stimulated. Osmotic pressure (osmotic gradient  
 118 established by NaCl and urea) between the lumen and the  
 119 interstitium facilitates the water reabsorption through the  
 120 water channels, resulting in urine concentration (Fig. 2)  
 121 [23]. This almost exclusive  $V_2$  receptor targeting results  
 122 in antidiuresis by increased urinary concentration, without  
 123 having a vasoconstrictor effect on the blood vessels.



**Fig. 2** Mechanism of action of desmopressin. 1: AVP binds to receptor, 2: receptor activates second messenger system, 3: cAMP binds PKA, 4: exocytosis aquaporin channels, 5: water absorption. AC adenylate cyclase, AQP2 aquaporin water channel AQP2WCV aquaporin 2 water channel-containing vesicles, ATP adenosine triphosphate, AVP arginine vasopressin, cAMP cyclic adenosine monophosphate, PKA protein kinase A,  $V_2R$   $V_2$  vasopressin receptor (adapted from [24])

## 4 Therapeutic Use in Nocturnal Enuresis in Children

124 According to the International Children's Continence Society (ICCS), enuresis or bedwetting means micturition dur-  
 125 ing sleep in a child of at least 5 years, the age at which bladder control should have been achieved [25]. Enuresis  
 126 is subdivided into monosymptomatic (MNE) and non-  
 127 monosymptomatic enuresis (NMNE), whereby for the lat-  
 128 ter, enuresis associated with symptoms of the lower urinary  
 129 tract including daytime incontinence is observed [26]. The  
 130 prevalence of enuresis is 12–25% in 5-year-old children,  
 131 6–8% in 8-year-old children, 2–3% in 12-year-old children  
 132 and 0.5–1.7% in adulthood [27, 28]. The prevalence rate is  
 133 higher in boys than in girls (2:1) [29], for which the reason  
 134 is unclear up to now. The cure rate is defined as the achieve-  
 135 ment of complete dryness without arousal [30]. The annual  
 136 spontaneous cure rate of enuresis is 14% in 5- to 9-year-  
 137 old children, 16% in 10- to 14-year-old children and 16%  
 138 in 15- to 19-year-old adolescents [30]. Not all patients with  
 139 enuresis will cure spontaneously, and persisting enuresis is  
 140 observed in 0.5–1.7% of the adolescents [11, 31]. Enuresis  
 141 can potentially lead to distress, which has an impact on the  
 142 child's self-esteem, social life, quality of sleep and school  
 143 performance [32]. Both the impact on the well-being of the  
 144 child as well as the persistence of enuresis in adolescents  
 145 necessitates an effective therapy [33]. This therapy requires  
 146 appropriate diagnosis of the enuresis type by proper screen-  
 147 ing of the patient, followed by administration and evaluation  
 148 of the prescribed therapy [34]. Desmopressin and enuresis  
 149 alarm are the only level 1 evidence and grade A first-line  
 150 enuresis treatments recommended by the International Con-  
 151 sultation on Incontinence [35].

152 Antidiuretic doses of the different formulations are listed  
 153 in Table 1. For enuresis, it is recommended to administer  
 154 oral desmopressin 1 h prior to bedtime, preferably without  
 155

**Table 1** Antidiuretic doses of different desmopressin formulations ( adapted from SPC Minirin® Ferring)

Formulation	Indication	Age	Dose	Dosing interval
Lyophilizate	Enuresis	Adult/child (> 5 years)	120–240 µg	1 per day, evening
	CDI	Adult/child (> 5 years)	60–120 µg	3 per day
	Nocturia	Adult/child (> 5 years)	60–240 µg	1 per day, evening
Nasal spray	CDI	Adult	10–20 µg	2 per day
Nasal drops	CDI	Adult	10–20 µg	2 per day
IV/IM/SC injection	CDI	Adult	1–4 µg	1 per day
	CDI	Child	0.4 µg	1 per day
PO tablet	Enuresis	Adult/child (> 5 years)	200–400 µg	1 per day, evening
	CDI	Adult/child (> 5 years)	100–200 µg	3 per day
	Nocturia	Adult/child (> 5 years)	100–400 µg	1 per day, evening

CDI central diabetes insipidus, IM intramuscular, IV intravenous, PO per oral, SC subcutaneous

simultaneous food intake [15, 36, 37]. 2 weeks after starting desmopressin therapy, dosages should be individually adapted, preferably according to anti-enuretic and anti-diuretic effects. In enuresis, the therapy should be re-evaluated every 3 months (treatment withdrawn for at least 1 week) to monitor if further treatment is required [38]. A structured withdrawal is required when discontinuing desmopressin treatment, to evaluate if enuresis reoccurs. This structured withdrawal is preferred over sudden termination, since it results in an increasing success rate and a decreasing relapse rate [39, 40]. Moreover, dose-dependent withdrawal (lowering the dose) results in less wet incidents in comparison with time-dependent withdrawal (increasing time between doses) and is therefore the preferred approach [41, 42].

#### 4.1 Desmopressin and Alarm Therapy

Several authors evaluated if combination therapy could be more beneficial than desmopressin monotherapy. Evaluating different types of therapy is necessary, however the results of these studies should be carefully interpreted since the lack of subtyping of enuresis might result in confounded results. Ideally, to assess these therapies, only carefully compared patients can be used as their own controls. Moreover, definitions about response rate of different therapies should be carefully interpreted, since for desmopressin therapy the decrease of number of dry nights is often used, whereas for alarm therapy the percentage of nights the child arouses for urination is determined [30]. Perrin et al. [43] and Peng et al. [44] performed a systematic literature review on alarm versus desmopressin monotherapy in children with MNE, showing that alarm therapy was preferred due to the lower relapse rate. However, the latter is only applicable to motivated children, since a much higher dropout rate was noted with the alarm [45, 46]. The latter conclusions were confirmed by a network meta-analysis performed by Song et al. [47].

#### 4.2 Desmopressin and Other Drugs

Lee et al. [48] evaluated the efficacy of desmopressin monotherapy versus desmopressin combined with oxybutynin (anticholinergic) and versus imipramine (tricyclic antidepressant) monotherapy in children with enuresis (5–15 years). The authors concluded that the efficacy of combination therapy was higher in comparison with both monotherapies. The latter was inconsistent with the results found by Naitoh et al. [49], where no significant differences between alarm monotherapy, desmopressin or imipramine and alarm combination therapy were observed. In a pilot study, De Guchtanaere et al. [50] demonstrated that addition of early morning furosemide (diuretic) significantly lowered nocturnal diuresis rates in children with MNE

resistant to desmopressin. Alloussi et al. [51] evaluated the combination of propiverine (antimuscarinic) and desmopressin in children with bedwetting. This combination therapy was highly effective, but a further decrease of the relapse rate (21.5%) and fine tuning of dosing regimens was still required. This combination was then optimized by Jabbour et al. [52], whereby the relapse rate decreased to 13%. However, it should be noted that the reported relapse rates might be an overestimation of the real-life situation, since only children who were unresponsive to monotherapy were included. Park et al. [53] demonstrated that a combination of desmopressin and an anticholinergic drug (oxybutynin, tolterodine [antimuscarinic], propiverine [antimuscarinic]) resulted in a more effective and faster response than desmopressin monotherapy. A possible role for the combination of desmopressin and oxybutynin in desmopressin monotherapy non-responders was confirmed by Radvanska et al. [54]. Azarfar et al. [55] demonstrated that the combination of desmopressin and tolterodine had a lower relapse rate than desmopressin and oxybutynin combination therapy. Kamperis et al. [56] administered either a combination of indomethacin (non-steroidal anti-inflammatory drug) and desmopressin, or a placebo and desmopressin, to children with MNE and desmopressin-resistant nocturnal polyuria. The authors concluded that there was an added effect of indomethacin to desmopressin therapy, leading to a greater reduction in nocturnal urinary output. However, the number of wet nights was not significantly different between combination and monotherapy.

## 5 Pharmacokinetics

The nasal route of administration is traditionally preferred for peptide drug delivery, since the relatively large surface area, thin epithelium and rich vascularization facilitate the absorption of these peptides. However, higher inter- and intra-subject variability in PK was observed following IN administration [57]. Subsequently, alternative routes of administration, such as the oral lyophilizate, were explored. Table 2 gives an overview of the PK parameter values of desmopressin administered via different formulations in humans. Only five papers described PK studies performed in the pediatric subpopulation for treatment of enuresis (highlighted in Table 2) [13–14, 15–17, 58, Dossche et al., submitted].

### 5.1 Absorption

Oral desmopressin is absorbed relative rapidly via a paracellular route in the duodenum and the proximal jejunum, reaching maximal plasma concentrations ( $C_{max}$ ) between 0.6 and 1.5 h after administration ( $T_{max}$ ) in healthy male

Table 2 Pharmacokinetic parameters of desmopressin in humans after various routes of administration

Route of administration	Disease state	Age (years)	Dose ( $\mu\text{g}$ )	CL (L/h)	$V_d$ (L)	$T_{1/2\text{el}}$ (h)	AUC <sub>inf</sub> (pg h/mL)	C <sub>max</sub> (pg/mL)	$T_{\text{max}}$ (h)	F (%)	References	
PO tablet	Healthy	20–57	200				25.4	13.6	1.2	0.1	[61]	
	Diabetes	30–43	200			2.0	50.3	16.2	1.5		[76]	
	Diabetes	30–43	200			2.0	50.3	16.2	1.5		[76]	
	Diabetes	30–43	200			2.0	50.3	16.2	1.5		[76]	
	Healthy	55–75	200				23	6.2	1.5	0.08	[66]	
	Healthy	23–45	400			2.5	90.4	25.4	1.3		[64]	
	Nocturia	65–78	400			3.3	70.7	14.2	1.5		[77]	
	Healthy	18–49	400				85.5	23.2	1.2		[78]	
	Healthy	18–49	400				91.2	28.2	1.1		[78]	
	Healthy	20–35	400			2.3	70.8	22.0	1.0		[36]	
	Healthy	20–35	50			1.4	1.7 <sup>c</sup>		1.0		[79]	
	Healthy	20–35	100			1.9	3.2 <sup>c</sup>		1.0		[79]	
	Healthy	20–35	200			2.4	7.0 <sup>c</sup>		2.0		[79]	
	Diabetes	21–52	200						1.0		[79]	
	Healthy	19–45	600			2.3	132.0	32.0	1.2		[80]	
	Healthy	18–45	600			2.7	229.6	64.2	1.0		[63] (fasted)	
	PO spray	Healthy	18–45	600			2.5	88.7	20.19	2.0		[63] (fed)
Healthy		21–29	160				59.0	15.5	1.0		[81]	
Healthy		21–29	240				110.9	29.8	0.7		[81]	
Healthy		21–29	320				137.3	41.6	0.9		[81]	
Healthy		20–32	19			2.8	372.0	103.3	0.8		[82]	
Healthy		20–57	20				63.0	21.3	1.0	3.4	[61]	
Healthy		20–32	9.5			2.7	135.4	34.1	0.8		[82]	
Healthy		20–34	20				116.9	31.2	0.7		[57]	
Healthy		20–34	20				108.9	30.0	0.6		[57]	
Diabetes		11–16	10–25						0.6		[57]	
SC injection	Diabetes	30–43	20			2.2	79.9	25.8	0.7		[79]	
	Healthy	20–57	2				202.5	62.3	0.7		[76]	
	Healthy	20–57	2			1.3	122.3			100	[61]	
	Enuresis	7–16	2			1.5		164	0.5–1	100	[58]	
	Healthy	22–46	2	10.4	28.2	2.0	197			100	[65]	
	Healthy	55–75	2	6.6	11.3	3.1	302	181		100	[66]	
	Renal dysfunction	20–76	0.3 $\mu\text{g}/\text{kg}$	1.6	22 <sup>d</sup>	9.7					100	[83]
	Healthy	20–32	240			2.1	67.4	17.9	1.5	0.25	[82]	
	Enuresis	7–16	120	4982 <sup>a</sup>	23,346 <sup>b</sup>						0.25	[15] <sup>e</sup>
	Enuresis	6–13	240	2330 <sup>a</sup>	8510 <sup>b</sup>							[13]
PO lyophilizate	Healthy	20–32	240			2.1	67.4	17.9	1.5	0.25	[82]	
	Enuresis	7–16	120	4982 <sup>a</sup>	23,346 <sup>b</sup>						[15] <sup>e</sup>	
Enuresis	6–13	240	2330 <sup>a</sup>	8510 <sup>b</sup>							[13]	

Table 2 (continued)

Route of administration	Disease state	Age (years)	Dose ( $\mu\text{g}$ )	CL (L/h)	$V_d$ (L)	$T_{1/2el}$ (h)	AUC <sub>inf</sub> (pg h/mL)	$C_{max}$ (pg/mL)	$T_{max}$ (h)	F (%)	References
	<b>Enuresis</b>	<b>0.5–8</b>	<b>60–240</b>	<b>1826<sup>a</sup></b>	<b>4018<sup>b</sup></b>	<b>1.6</b>	<b>104</b>	<b>41</b>	<b>1</b>		<b>Dossche et al., submitted [17]<sup>f</sup></b>
	<b>Enuresis</b>	<b>0.5–16</b>	<b>0–480</b>	<b>4960<sup>a</sup></b>	<b>1090<sup>b</sup></b>						

Bolded text indicates pharmacokinetic parameters of desmopressin in children

AUC<sub>inf</sub> area under the plasma concentration–time curve, CL clearance,  $C_{max}$  maximal plasma concentration, F absolute bioavailability, IV intravenous, PO per os, SC subcutaneous, SL sublingual,  $T_{1/2el}$  elimination half-life,  $T_{max}$  time at maximal plasma concentration,  $V_d$  volume of distribution

<sup>a</sup>CL/F

<sup>b</sup> $V_d/F$

<sup>c</sup>pmol/h

<sup>d</sup> $V_{ss}$

<sup>e</sup>Population PK estimated based on Osterberg et al. [13] and De Bruyne et al., [14]

<sup>f</sup>Population PK estimated based on Osterberg et al. [13], De Bruyne et al. [14] and Dossche et al.

adults [59, 60]. Overall, the oral bioavailability in healthy adults is extremely low (0.08–0.16%), since desmopressin is enzymatically degraded in the lumen of the gastrointestinal tract and the high molecular weight of desmopressin makes the paracellular absorption inefficient [19]. Moreover, absorption via a transcellular route seems less likely, due to the negative clog P (–7.711) observed for desmopressin. Osterberg et al. [13] stated that the oral absorption process of desmopressin might be different for children (enuresis, ages 6–13 years), since the mean transit time was significantly different in comparison with adults (children: 0.21 h, adults: 0.48 h). This observation could be attributed to a maturational change in absorptive surfaces, gastric emptying and/or intestinal motility. The bioavailability following IN administration in healthy adults is better (3–5%) when compared with oral (PO) administration [61].

Gasthuys et al. [16] evaluated the PK of desmopressin lyophilizate in growing piglets (Belgian Landrace  $\times$  large white; 8 days, 4 weeks, 7 weeks, 6 months of age) using population PK modeling. This was the first study demonstrating a dual sequential absorption process, with a double peak present in the absorption phase, probably attributed to transmucosal absorption in the oral cavity and the small intestine. This observation was also hypothesized by Michelet et al. [62], who found a discrepancy when linking their previously published PK model [15] to their PD parameters in children. The authors observed a significant effect of the formulation on the IC<sub>50</sub> (half maximal inhibitory concentration), which is physiologically implausible since only at the PK side a formulation effect is expected. A possible explanation was that the model was not able to capture the absorption part due to the sparse sampling design applied in the human pediatric studies, resulting in a mismatch between the PK and the PD models. Two possible hypotheses were proposed to explain this mismatch: (1) fast absorption of the lyophilizate, potentially missing a larger absorption peak or (2) occurrence of two absorption peaks. To confirm one of these hypotheses, Dossche et al. performed a clinical PK/PD study in children applying a rich sampling design during the absorption phase. In this study, the double absorption peak was confirmed in growing children (6 months to 8 years of age, especially 60 and 120  $\mu\text{g}$  lyophilizate). Moreover, Michelet et al. [17] reanalyzed their previously published pediatric PK/PD model including the newly generated clinical data, which resolved the previous stated discrepancy and confirmed the double absorption peak hypothesis.

Rittig et al. [36] investigated the effect of food intake on the absorption after PO administration of 400  $\mu\text{g}$  desmopressin to healthy adults aged 20–35 years. Concomitant administration of desmopressin and a standard meal (2199 kJ, Big Mac<sup>®</sup>) and administration of desmopressin 1.5 h after eating a standard meal resulted in a reduced (50% lower  $C_{max}$ ) and delayed absorption (longer  $T_{lag}$  and higher  $T_{max}$  with



an increase from 0.25 h to 0.5 h and 1 h to 1.5 h, respectively) in comparison with fasted patients. These observations were confirmed in a more recent study performed in Chinese healthy adults aged 18–45 years [63]. Two possible explanations were proposed for these observations: (1) the binding of desmopressin to food particles or (2) the interaction of food with intestinal metabolic activity (increase in peptidase production). Michelet et al. [15] pooled pediatric data from two PK desmopressin trials in children and developed a model using a population PK approach on a sparse sampling set to understand the effect of food intake on the absorption of desmopressin (120 µg lyophilizate and 200 µg tablet). The effect of concomitant food intake was found to be clinically significant and might influence the bioavailability and therefore the optimal dosing of desmopressin [17]. The latter was confirmed in another analysis, with the addition of lyophilizate data generated in the recently performed study of Dossche et al. in fasted younger children.

Callréus et al. [64] investigated the effect of the gastrointestinal motility and gastrointestinal secretion by administering erythromycin (increasing motility, 250 mg every 6 h, first dose 3 days before the study and last dose at –1 h) and loperamide (slowing motility, 4 mg, –24 h, –12 h and –1 h) prior to PO administration of 400 µg desmopressin to healthy volunteers (23–45 years). A significant increase in  $C_{\max}$  and  $T_{\max}$  was observed when desmopressin was administered after pre-treatment with loperamide, while no significant difference in absorption was observed with erythromycin. The latter observations still need to be confirmed in the pediatric population.

## 5.2 Distribution

The volume of distribution ( $V_d$ ) of desmopressin after IV injection is 28.2 L in 22- to 46-year-old subjects and 11.2 L in 55- to 75-year-old subjects [65, 66]. In children aged 6–12 years, the mean population PK estimate of apparent  $V_d$  after administration of an oral lyophilizate was 8510 L, which would correspond to a systemic  $V_d$  of 21.3 L (assuming 0.25% bioavailability) [13]. This result was in accordance with the result (8237 L) obtained by Michelet et al. [15]. The latter authors also observed an effect of body weight on  $V_d$ , indicating that dose adjustment might be required. Information about the plasma protein binding of desmopressin is rather scarce. Lawton and Witty [19] mentioned that 50% of the absorbed desmopressin binds to plasma proteins. Desmopressin does not cross the blood–brain barrier after IV administration to patients aged 36–72 years [67]. Burrow et al. [68] determined desmopressin concentrations in breast milk in a 23-year-old woman with diabetes insipidus. They concluded that desmopressin seems to be a safe therapy, since only traces of desmopressin (max. 7 ng/L at 40 min post-administration) were found in breast milk. However, it

should be noted that this study was only performed in one patient, so additional studies are required.

## 5.3 Metabolism

An in vitro study in rats demonstrated that 20% of desmopressin was inactivated by the liver and only a small fraction by the kidney [69]. Fjellstad-Paulsen and Lundin [70] determined the degradation of AVP and desmopressin in human renal microvilli brush-border membranes and human liver membranes. Arginine vasopressin was found to be degraded in the kidney at both the C- and N-terminus as well as by disulphide cleavage when the cofactor glutathione was present, and was found to be stable without this cofactor. However, degradation of desmopressin in the kidney was negligible even when glutathione was present. No degradation was observed when desmopressin was incubated with purified liver cell membranes, since desmopressin might undergo receptor-mediated endocytosis followed by intracellular metabolism. This theory was also supported by Lundin et al. [71], where rapid removal of desmopressin from the incubation medium was observed after incubation of desmopressin with liver tissue slices. Removal can be a consequence of binding to hepatic vasopressin receptors or internalization followed by intracellular degradation. Enzyme-dependent proteolysis of desmopressin by pancreatic enzymes in jejunal and ileal juice also occur. Degradation of desmopressin appears slower in jejunal than ileal juice; since it is pH dependent, it is more stable at acidic pH [72]. To confirm the theory of enzyme-dependent proteolysis of desmopressin, concomitant administration of aprotinin (broad-spectrum proteinase inhibitor) and desmopressin was studied. A concentration-dependent inhibition of desmopressin degradation was indeed observed, enhancing the bioavailability of orally administered desmopressin [73].

## 5.4 Excretion

The mean population PK values of apparent clearance for children (6–12 years) and adults (18–54 years) was 2330 L/h and 2930 L/h, respectively [13, 15]. The main route of elimination of desmopressin is renal excretion. Fjellstad-Paulsen et al. [61] determined the urinary excretion after IN, subcutaneous (SC) and PO administration (IN: 20 µg; SC: 2 µg; PO: 200 µg) in healthy adults aged 20–57 years. Forty-eight percent, 92% and 65% of the amount absorbed after SC, IN and PO administration, respectively, was excreted in urine within 24 h. However, the renal fraction in the pediatric population still needs to be determined. The renal fraction of desmopressin after IV administration (4 µg) was 39% [74]. Moreover, Agerso et al. [74] investigated the correlation between creatinine clearance and renal clearance in both healthy volunteers and renally impaired patients (aged

49–68 years) and found that both renal and non-renal excretion of intravenous desmopressin varied with creatinine clearance. A decrease of 1.67% in creatinine clearance led to a 1.74% decrease in renal clearance and a 0.93% decrease in nonrenal clearance of desmopressin. This observation could possibly be attributed to the association of renal impairment and a decrease in hepatic metabolism. Moreover, a prolongation of the elimination half-life ( $T_{1/2el}$ ) was observed. Since desmopressin is only partially eliminated (39%) by the kidney, the total clearance of desmopressin is less affected by renal function. Consequently, desmopressin is still well tolerated in renally impaired patients. However, when administering high doses of desmopressin, adverse effects may occur in those patients, so great caution should be exercised when establishing the exact dosing regimen. Lundin et al. [71] determined the excretion of desmopressin in bile after various routes of administration (intraduodenal, intrajugular and intraportal) in one conscious pig (Swedish Landrace, 4 months old). Only low concentrations of desmopressin were retrieved in bile, < 1% of the available dose. The  $T_{1/2el}$  after PO administration of desmopressin is prolonged in comparison with endogenous AVP, since its enzymatic degradation in liver and kidney are slower [75].

## 6 Pharmacodynamics

About 6–10% of children aged 7–8 years suffer from bedwetting; however, only 60–70% are responders (complete or partial responders) to desmopressin treatment [84–86]. Despite the low oral bioavailability, the plasma concentrations are sufficient to achieve antidiuretic effects. This can be attributed to high receptor affinity and binding capacity of desmopressin to the V2 receptor [19]. Ideally, the duration of action of desmopressin for treating bedwetting should vary between 8 and 11 h, since longer durations could induce adverse effects (hyponatremia, seizures and abdominal pain). Multiple studies demonstrated the efficacy (reducing the number of wet incidents, reducing 24-h urine production) of the different desmopressin formulations in children with enuresis [87–93].

### 6.1 Formulation Effect

Various formulations of desmopressin have been used to treat bedwetting. De Guchtenaere et al. [94] compared an oral lyophilizate tablet (120 µg) with a conventional tablet (200 µg) in children aged  $12.1 \pm 2.5$  years (enuresis) and concluded that the lyophilizate has a higher concentrating capacity and requires a shorter time to reach maximal effect in comparison with the tablet. De Bruyne et al. [14] performed a relative bioavailability study of a 200-µg tablet compared with a 120-µg lyophilizate in children aged

5–18 years (enuresis). Relative bioavailability between both formulations was found, but the smaller inter- and intra-subject variability in plasma concentration and better predictability of plasma concentrations makes the lyophilizate more reliable in comparison with the tablet. However, Michelet et al. [15] constructed a population PK model based on pooled data from the studies of Osterberg et al. [13] and De Bruyne et al. [14], whereby the claimed bioequivalence between the two formulations in adults (200-µg tablet and 120-µg lyophilizate) could not be extrapolated to children. Moreover, in a follow-up modeling study, after inclusion of the data generated by Dossche et al., Michelet et al. [17] found that bioequivalence of the two formulations could not be claimed in children due to differences in absorption and the impact of food and age (0.5–16 years). Lottman et al. [95] also compared efficacy and safety between the lyophilizate (120–240 µg) and the tablet (200–400 µg) in children (5–15 years) with enuresis. Both formulations were well tolerated and no adverse effects related to the study treatment were observed. The incidence of enuresis events measured during a 6-week cross-over study (3 weeks formulation one [tablet or lyophilizate] followed by 3 weeks formulation two [lyophilizate or tablet]) was comparable between both formulations. Higher compliance was achieved with the lyophilizate, since it circumvents the difficulties observed when children need to swallow desmopressin tablets. The latter was also confirmed by Juul et al. [96], whereby a higher patient compliance and consequently increased treatment outcome was observed with the lyophilizate (5–15 years, enuresis). Rembratt et al. [66] determined the PD parameters of desmopressin (PO: 200 µg; IV: 2 µg) and the influence of the circadian rhythm on those parameters in male patients aged 55–75 years (high incidence of nocturia). The PD effects were almost identical for both formulations during the first 6 h; however, the duration of action of the IV administration lasted longer. When the PD parameters of desmopressin administration during daytime or nighttime are compared, the effects on urine production and osmolality were prolonged to 12 h at nighttime, possibly due to the additive effect of desmopressin and endogenous vasopressin at night. This observation should also be evaluated in the pediatric population.

### 6.2 Dose–Effect

Schulman et al. [22] performed an 8-week dose titration study with a desmopressin tablet in children with bedwetting (aged 6–16 years). The starting dose was set at 200 µg, followed by an increase in 200-µg increments (evaluation every 2 weeks) until dryness or the maximum dose of 600 µg was achieved. A linear dose–response relationship was noted, meaning that the reduction in the number of wet nights per 2 weeks (number of nights reduced by 50% compared with

the baseline) is linearly related to the administered desmopressin dose.

Vande Walle et al. [37] performed one of the first dose-titration studies (30, 60, 120, 240, 360 and 480 µg) of desmopressin lyophilizate to assess the PD measurements in enuretic children aged 6–12 years (urinary volume, osmolality and duration of action). A decline in urinary output and maximum osmolality (> 800 mOsm/kg bodyweight) was observed 1 h post-administration for the 60- to 480-µg dosing. Maximum effect of the 30-µg dose was also achieved after 1 h, but maximum osmolality was lower in comparison with the other doses. Since the maximum effect is reached 1 h after dosing, it is important to administer the lyophilizate 1 h prior to bedtime. The duration of action is around 6 h for 120 µg and > 8 h for > 120-µg doses, enabling control of diuresis for 7–11 h (≈ approximately one night). Since the maximum osmolality, duration of action and urinary output are comparable between the 240-, 360- and 480-µg doses and most enuresis events occur during the first 2 h of sleep [97], a dose range of 120–240 µg should be sufficient. The lower doses also reduce the risk of adverse effects. Ferrara et al. [98] performed a 9-week dose titration study with a desmopressin lyophilizate in children with enuresis (aged 5–18 years), followed by an observation period of 3 months (responders). The starting dose was set at 120 µg, followed by an increase to 180 µg (partial responders at 120 µg, evaluation after 3 weeks) and 240 µg (partial responders at 180 µg, evaluation after 3 weeks). The non-responders were excluded from the study. In this study, only a limited number of patients had a further improvement of symptoms (14.3%) or were complete responders (9.5%) after titrating the dose to 180 µg. No improvement of the symptoms was observed when the dose was further titrated to 240 µg, which demonstrates the need to prescribe the right dose to the right patient. Michelet et al. [17] evaluated if the current standard dosing regimens (120 µg) were sufficient for children who were not fasted when taking desmopressin before bedtime. The authors concluded that the current dosing using lyophilizate was inappropriate, whereby new and simple simulated dosing schemes based on age or weight were proposed (age based: 30 µg [< 2 years], 60 µg [2–4 years], 120 µg [4–8 years], 180 µg [8–12 years], 240 µg [+ 12 years]; weight based: 45 µg [< 12.5 kg], 90 µg [12.5–25 kg], 180 µg [25–50 kg], 360 µg [50–100 kg]).

### 6.3 Food Effect

Rittig et al. [36] investigated the effect of food intake on the antidiuretic action of desmopressin after PO administration of two 200-µg tablets to healthy adults aged 20–35 years. Despite the reduced and delayed absorption of desmopressin, concomitant administration of a standard meal and desmopressin did not significantly alter the antidiuretic

response to desmopressin 400 µg during the first 4 h post-administration. However, the duration of action was prolonged in fasted pediatric patients in comparison with fed pediatric patients, since the plasma drug concentrations were significantly higher [17].

### 6.4 Predictors of Response

An anti-enuretic response, namely a reduction in number of wet nights of 100% (complete responder) or of 50–99% (partial responder), is achieved in 60–70% of the children treated with desmopressin [25, 35, 99]. Thirty to forty percent of the patients are non-responders, probably attributed to small nocturnal bladder capacity and detrusor-dependent nocturnal enuresis. Despite the proven success rate, a high relapse rate (78%) after short-term desmopressin treatment is observed, whereas the relapse rate was decreased when administration was maintained for longer [35]. The high relapse rate and the number of non-responders render it necessary to use a pragmatic approach for the treatment of bedwetting, whereby careful consideration of the position of desmopressin within this treatment is required.

Different underlying pathophysiological mechanisms of enuresis could explain the differences in response to desmopressin [100]. An anti-enuretic response of desmopressin is expected when patients are able to increase their urinary osmolality [11]. Nevéus et al. [58] studied the difference in PD effects after IV injection of desmopressin (2 mg) to children aged 7.6 and 16.2 years (enuresis). Half of the study population ( $n=6$ ) were responders and half ( $n=6$ ) were non-responders to the treatment. Enuresis only occurred in the non-responder group. It appears that in both responders and non-responders a low nocturnal urine production and high morning urine osmolality was present. A higher urinary output of less concentrated urine was produced by the responders, whereas non-responders voided with smaller bladder volumes. The latter is probably due to instability of the bladder. Rushton et al. [101] evaluated if maximum functional bladder capacity (as a percent of predicted bladder capacity) could predict response to desmopressin in enuretic children aged 8–14 years. The authors observed that when the maximum functional bladder capacity exceeded the mean capacity of the studied patients (= 70% of the age predicted capacity), the likelihood of response increased twofold. Hogg and Husmann [102] found that there was a good correlation (91%) between successful therapy response to desmopressin and a positive familial nocturnal enuresis history, whereas a poor correlation was noted when the family history was negative (7%). The latter was in contrast to the results found by Schaumburg et al. [103], where successful therapeutic response could not be predicted by a positive family history. Devitt et al. [104] investigated the relationship between nocturnal concentrations of AVP and the



610 response to desmopressin, which combined with physiologi- 663  
 611 cal factors might predict a successful response. The authors 664  
 612 observed a correlation between response to desmopressin 665  
 613 and nocturnal AVP concentrations, which is influenced by 666  
 614 neuronal patterning during early infancy (maturation of neu- 667  
 615 ronal networks involving the hypothalamic pituitary axis and 668  
 616 AVP production). The best predictive physiological factors 669  
 617 were (1) breast feeding; (2) mean nocturnal AVP concen- 670  
 618 tration and (iii) height. Moreover, an inverse correlation 671  
 619 with low birth weight and poor linear growth was noted. 672  
 620 Kruse et al. [105] evaluated predictive factors (age, gender, 673  
 621 heredity, sleep pattern, previous treatments, number of wet 674  
 622 incidents and dosing regimens) for successful desmopressin 675  
 623 treatment (6–12 years, MNE). No specific predictors could 676  
 624 be identified, possibly because the pathology of enuresis 677  
 625 needs to be considered to evaluate the predictors and the 678  
 626 success rate of the therapy. Van Herzeele et al. [106] also 679  
 627 evaluated predictive parameters for desmopressin response 680  
 628 (number of wet nights a week, fluid intake, daytime voiding 681  
 629 frequency, diuresis, age, body mass index, country, family 682  
 630 history and sex), whereby only nocturnal diuresis volume 683  
 631 (volume of 180, 300, 400 mL: 11%, 20%, 60% complete 684  
 632 responders, respectively) and the number of wet nights a 685  
 633 week (limited number increases response rate) were con-  
 634 sidered good predictors (aged 5–15 years, enuresis). When  
 635 looking at the demographic variables, only age was consid-  
 636 ered significant; the response rate in younger children was  
 637 significantly lower than in adolescents. Van Herzeele et al.  
 638 [107] also evaluated if the patient's motivation and compli-  
 639 ance can influence the response rate. The compliance in  
 640 723 children treated with desmopressin tablets for 6 months  
 641 or less was determined and the authors concluded that a  
 642 decreased compliance was related to a lower response rate.

643 The PD response of desmopressin is different between 686  
 644 male and female patients, with a higher antidiuretic efficacy 687  
 645 observed in adult females [12, 65]. Juul et al. [108] exam- 688  
 646 ined the sex difference in antidiuretic response in patients 689  
 647 with nocturia (> 2 voids/night and serum sodium concen- 690  
 648 tration > 135 mmol/L) and healthy volunteers. The mean 691  
 649 decrease in nocturnal urine volume was higher in females 692  
 650 than males. Moreover, the decrease in sodium plasma con- 693  
 651 centrations was more profound in females, potentially caus- 694  
 652 ing hyponatremia in those patients, whereby a narrower 695  
 653 therapeutic window should be applied. The exact mecha- 696  
 654 nisms to explain those differences are still unidentified, 697  
 655 but different expression of the V<sub>2</sub> receptor in males versus 698  
 656 females could be a possible explanation. Liu et al. [109] 699  
 657 examined the expression of V<sub>2</sub> receptor mRNA and protein 700  
 658 in kidneys of female and male Sprague–Dawley rats, and 701  
 659 linked the dimorphic traits between the sexes and pheno- 702  
 660 typic variability among female heterozygotes to the second 703  
 661 'silenced' X-chromosome. Some genes escape the inactiva- 704  
 662 tion of the second X-chromosome, whereby a variability in 705  
 706  
 707  
 708  
 709  
 710  
 711  
 712

663 gene expression could be observed. Carrel and Willard [110] 664  
 665 demonstrated that the V<sub>2</sub> receptor has a high probability to 666  
 667 escape inactivation, potentially leading to expression of 668  
 669 this gene from both X-chromosomes in females. However, 670  
 671 further research is required to completely understand the 672  
 673 sex differences in antidiuretic response of desmopressin. 674  
 675 Schroeder et al. [111] determined if there were sex-related 676  
 677 differences in renal sensitivity to desmopressin in Danish 678  
 679 children with nocturnal enuresis (mean age 9.2 years). In 680  
 681 this study, a greater percentage of girls than boys had a long- 682  
 683 term effect of the lowest desmopressin lyophilizate dose, 684  
 685 confirming the theory that girls could possibly be more  
 686 sensitive to desmopressin than boys. However, the authors  
 687 noted that the difference between girls and boys was rather  
 688 small, necessitating additional studies to further confirm this  
 689 theory. When administering the tablet and the nasal spray, no  
 690 sex-related differences were observed, possibly attributed to  
 691 the fact that sex differences were only observed at the low-  
 692 est desmopressin doses, as the doses of the tablet and the  
 693 nasal spray were high. For both boys and girls, no hospital  
 694 diagnoses of hyponatremia were documented for any of the  
 695 mentioned formulations.

## 7 Adverse Events 685

686 The safety of different desmopressin formulations has been 687  
 688 thoroughly researched. The use of desmopressin is consid- 689  
 690 ered safe but additional preventive measures should be taken 691  
 692 in order to prevent severe hyponatremia. In 1987, Fjellstad- 693  
 694 Paulsen et al. [112] compared the tolerability of IN and PO 694  
 695 desmopressin administration in children with enuresis (aged 695  
 696 6–14 years) and did not observe any significant adverse events 696  
 697 related to these formulations (two patients experienced nasal 697  
 698 discomfort and three patients experienced epistaxis). Li Volti 698  
 699 et al. [113] and Akoğlu et al. [114] did not observe any effect 699  
 700 on nasal cytology and mucociliary clearance after 6 months 700  
 701 of nasal spray therapy in children aged 6–16 years. Desmo- 701  
 702 pressin does not affect sleep directly, but responders exhibit 702  
 703 more rapid-eye-movement sleep than non-responders, which 703  
 704 might be caused by differences in vasopressin secretion [115]. 704  
 705 Dehoorne et al. [116] evaluated clinical symptoms of water 705  
 706 intoxication after administration of desmopressin nasal spray 706  
 707 to 2043 pediatric patients (1999–2004). Fifteen children (aged 707  
 708 6–15 years) were identified to have water intoxication result- 708  
 709 ing in vomiting, headache, decreased consciousness, seizures 709  
 710 and hyponatremia. The authors concluded that these symp- 710  
 711 toms were secondary to a prolonged desmopressin bioactiv- 711  
 712 ity, that is, prolonged maximal urinary concentration capacity 712  
 and delayed restoration of daytime diluting. Moreover, Gla-  
 zener and Evans [99] found 21 case reports of water intoxi-  
 cation (< 1,993), probably due to over-drinking at bedtime,  
 as a maximum concomitant fluid intake during the night of



200–240 mL was recommended. The latter is also confirmed by Thumfart et al. [117], Vande Walle et al. [9], Lucchini et al. [118] and Kamperis et al. [34]. Del Gado et al. [119] evaluated the safety of desmopressin using either the nasal spray or the tablet (initial dose: 20 µg; maximum dose: 40 µg). Only transient, mild side effects were observed. Kano and Arisaka [120] administered desmopressin nasal spray (10 µg, uptitrated to 20 µg when patients remained incontinent after 4 weeks) for long-term treatment (between 12 and 24 weeks) of children (aged 6–15 years) diagnosed with enuresis. The authors did not observe any significant adverse effects (one patient had acute rhinitis and one patient had an event of excitement) and concluded that the nasal spray is safe and effective for long-term treatment in children with enuresis. The latter was also concluded in the studies performed by Knudsen et al. (MNE [121]), Hjälmås et al. (MNE [88]) and Läckgren et al. (refractory enuresis [89]). Alloussi et al. [122] reviewed 99 studies (7422 patients, children aged > 5 years to adolescents), whereby a low number of case reports [123–125] and post-marketing safety data demonstrated a higher risk of hyponatremia when administering nasal formulations. Despite the fact that hyponatremia events are rather rare, the authors made a plea for safety analysis, and not only limited to nasal formulations, by using routine laboratory testing. In comparison with IN administration, PO administration has a decreased risk of hyponatremia. Robson et al. [10] determined potential risk factors for hyponatremia: (1) excessive fluid intake, (2) overdosing, (3) age (< 6 years) and (4) interactions with other drugs. Van Herzeele et al. [126] performed a prospective study to determine the safety of desmopressin tablets in 744 children with bedwetting (aged 5–15 years), whereby no drug-related adverse events were observed. Ferrara et al. [127] included 237 enuretic children (5–18 years) to determine the adverse events of the lyophilizate based on their personal experience. Twenty-two children reported mild transient adverse events. This study demonstrated that the lyophilizate is safe to treat children with enuresis. Juul et al. [108] demonstrated a sex difference in incidence of hyponatremia in adults, whereby adaptation of the dose stratified by sex was required. For adult women, a dose of 25-µg lyophilizate is considered efficacious and safe, whereas for adult men this dose was 50- to 100-µg lyophilizate. To date, the latter still needs to be determined in the pediatric population, since only non-gender adapted doses (60- to 360-µg lyophilizate) were proposed in this population.

## 8 Conclusion

For more than 40 years, desmopressin has been mostly prescribed to children (approximately 90%) and investigated in adults. Despite the fact that desmopressin is generally accepted for the treatment of children with enuresis, there are still a lot of research questions that need to be

addressed concerning the pharmacology of desmopressin in the pediatric population. The current review summarized the available literature concerning this topic, whereby the need for additional PK/PD studies in children was demonstrated. The following research questions remain:

- *Double absorption peak* Due to the rich sampling strategy applied in a recent study (Dossche et al.), a double absorption peak was observed in the plasma concentration–time profiles of the younger children administered a lyophilizate (aged 6 months to 8 years). Further studies are required to determine the clinical relevance (efficacy and safety) of this double absorption peak.
- *Food effect* A profound food effect on oral bioavailability was demonstrated, necessitating administration of desmopressin without concomitant food ingestion. The latter is rather difficult to achieve in younger children, though a dose regimen adaptation can be considered. However, the fed patients were older than 8 years of age and the young fasted patients only received a lyophilizate. Consequently, the food effect should be confirmed in fed young patients and fasted young patients receiving a tablet as well.
- *Bioequivalence and therapeutic equivalence* The claimed equivalence in adults (120-µg lyophilizate and 200-µg tablet) cannot just be extrapolated to children based on data obtained from clinical trials in adults alone. Observed differences in absorption of both formulations is probably attributed to a food and maturation effect. However, to be able to compare these formulations thoroughly, acquiring additional data (cfr. section double absorption peak and food effect) is required.
- *Dosing regimen* At the moment, flat dose regimens for the lyophilizate (60–480 µg) are applied for all children. However, these dosing regimens might not be appropriate since the target attainment is only 33.4%, resulting in suboptimal or too prolonged effects. It might be more appropriate to use bodyweight (< 4 years) or age-dependent (> 4 years) dose regimens as proposed by Michelet et al. [17]. These proposed dose regimens should be tested in a follow-up clinical trial, whereby the PD response measured by biomarkers (i.e. baseline urine osmolality, diuresis or aquaporin levels) should be considered. The same exercise should be performed for the tablet formulation. Moreover, in these trials, dose stratification by gender should be considered.
- *Study endpoints* In future studies it might be helpful to evaluate both anti-diuretic and anti-enuretic effect by performing a 1-day intensive PK/PD sampling, followed by the registration of the number of wet nights and diuresis in the following 14 days. The change or reduction of number of wet nights and the PK/PD of both formula-

815 tions might be linked using, for example, time-to-event  
816 modeling.

817 **Acknowledgements** The help of Charlotte Van Herzezele and Pauline  
818 De Bruyne in retrieving possible literature for this review was grate-  
819 fully appreciated.

820 **Author contributions** All authors contributed to the review concep-  
821 tion and design. The first draft of the manuscript was written by Elke  
822 Gasthuys and Lien Dossche and all authors commented on previous  
823 versions of the manuscript. All authors critically revised and approved  
824 the final manuscript.

## 825 Compliance with Ethical Standards

826 **Funding** Elke Gasthuys, Lien Dossche and Robin Michelet were sup-  
827 ported by a doctoral fellowship from the Agency for Innovation by Sci-  
828 ence and Technology in Flanders (IWT) through the 'SAFEPEDRUG'  
829 project (IWT/SBO 130033). Jens Peter Nørgaard is supported by a  
830 Ferring Grant (Guest professor).

831 **Conflict of Interest** Elke Gasthuys, Lien Dossche, Robin Michelet,  
832 Jens Peter Nørgaard, Mathias Devreese, Siska Croubels, An Vermeu-  
833 len, Jan Van Bocxlaer and Johan Vande Walle declare that they have no  
834 conflict of interest related to the manuscript.

835 **Availability of Data and Material** Data sharing not applicable to this  
836 article since no datasets were generated or analyzed during the cur-  
837 rent study.

## 838 References

- 839 1. Vávra I, et al. Effect of a synthetic analogue of vasopres-  
840 sin in animals and in patients with diabetes insipidus. *Lancet*.  
841 1968;1(7549):948–52.  
842 2. Post EM, et al. Desmopressin response of enuretic children.  
843 Effects of age and frequency of enuresis. *Am J Dis Child*.  
844 1983;137(10):962–3.  
845 3. Ooi HL, Maguire AM, Ambler GR. Desmopressin administration  
846 in children with central diabetes insipidus: a retrospective review.  
847 *J Pediatr Endocrinol Metab*. 2013;26(11–12):1047–52.  
848 4. De Waele K, et al. Desmopressin lyophilisate for the treatment of  
849 central diabetes insipidus: first experience in very young infants.  
850 *Int J Endocrinol Metab*. 2014;12(4):e16120.  
851 5. Mannucci PM, et al. Mechanism of plasminogen activator and  
852 factor VIII increase after vasoactive drugs. *Br J Haematol*.  
853 1975;30:81–93.  
854 6. Mannucci PM, et al. 1-deamino-8-D-arginine vasopressin: a new  
855 pharmacological approach to the management of haemophilia  
856 and von willebrand's disease. *Lancet*. 1977;1(8017):869–72.  
857 7. Aronson AS, Svenningsen NW. DDAVP test for estimation of  
858 renal concentrating capacity in infants and children. *Arch Dis*  
859 *Child*. 1974;49(8):654–9.  
860 8. Radó JP. 1-desamino-8-D-arginine vasopressin (DDAVP) con-  
861 centration test. *Am J Med Sci*. 1978;275(1):43–52.  
862 9. Vande Walle J, et al. Desmopressin 30 years in clinical use: a  
863 safety review. *Curr Drug Saf*. 2007;2(3):232–8.  
864 10. Robson WLM, Leung AKC, Nørgaard J-P. The comparative  
865 safety of oral versus intranasal desmopressin for the treatment  
866 of children with nocturnal enuresis. *J Urol*. 2007;178:24–30.

- 867 11. Vande Walle JGJ, Van Herzezele C, Raes A. Is there still a role  
868 for desmopressin in children with primary monosymptomatic  
869 nocturnal enuresis? A focus on drug safety issues. *Drug Saf*.  
870 2010;33:261–71.  
871 12. Goessaert A-S, et al. Pharmacokinetics and pharmacodynamics  
872 of the oral disintegrating tablet of desmopressin in adults with  
873 nocturnal polyuria: a pilot study. *Adv Ther*. 2015;32:799–808.  
874 13. Osterberg O, et al. Pharmacokinetics of desmopressin admin-  
875 istrated as an oral lyophilisate dosage form in children with  
876 primary nocturnal enuresis and healthy adults. *J Clin Pharma-*  
877 *col*. 2006;46:1204–11.  
878 14. De Bruyne P, et al. Pharmacokinetics of desmopressin admin-  
879 istered as tablet and oral lyophilisate formulation in children  
880 with monosymptomatic nocturnal enuresis. *Eur J Pediatr*.  
881 2014;173:223–8.  
882 15. Michelet R, et al. Effects of food and pharmaceutical formula-  
883 tion on desmopressin pharmacokinetics in children. *Clin Phar-*  
884 *macokinet*. 2016;55:1159–70.  
885 16. Gasthuys E, et al. Population pharmacokinetic modeling of a  
886 desmopressin oral lyophilisate in growing piglets as a model  
887 for the pediatric population. *Front Pharmacol*. 2018;9:41.  
888 17. Michelet R, et al. An integrated paediatric population PK/PD  
889 analysis of dDAVP: how do PK differences translate to clinical  
890 outcomes? *Clin Pharmacokinet*. 2020;59(1):81–96.  
891 18. Zaoral M, Kolc J, Sorm F. Amino acids and peptides. LXXI.  
892 Synthesis of 1-deamino-8-D-γ-aminobutyryne-vasopressin,  
893 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-  
894 arginine-vasopressin. *Collect Czech Chem Commun*.  
895 1967;32:1250–7.  
896 19. Lawton G, Witty DR. Progress in medicinal chemistry. Amster-  
897 dam: Elsevier; 2013.  
898 20. Edwards CRW, Kitau MJ, Besser GM. Vasopressin analogue  
899 DDAVP in diabetes insipidus: clinical and laboratory studies.  
900 *Br Med J*. 1973;3:375–8.  
901 21. Robinson AG. DDAVP in the treatment of central diabetes insipi-  
902 dus. *N Engl J Med*. 1976;294(10):507–11.  
903 22. Schulman SL, Stokes A, Salzman PM. The efficacy and safety of  
904 oral desmopressin in children with primary nocturnal enuresis. *J*  
905 *Urol*. 2001;166(6):2427–31.  
906 23. Robben JH, Knoers NVAM, Deen PMT. Regulation of the vaso-  
907 pressin V2 receptor by vasopressin in polarized renal collecting  
908 duct cells. *Mol Biol Cell*. 2004;15(12):5693–9.  
909 24. Finley JJ, Marvin A, Udelson JE. Arginine vasopressin antago-  
910 nists for the treatment of heart failure and hyponatremia. *Circula-*  
911 *tion*. 2008;118:410–21.  
912 25. Austin PF, et al. The standardization of terminology of lower  
913 urinary tract function in children and adolescents: Update  
914 report from the standardization committee of the Interna-  
915 tional Children's Continenence Society. *Neurourol Urodyn*.  
916 2016;35(4):471–81.  
917 26. Nevés T, et al. The standardization of terminology of lower  
918 urinary tract function in children and adolescents: report from  
919 the Standardisation Committee of the International Children's  
920 Continenence Society. *J Urol*. 2006;176(1):314–24.  
921 27. Canadian Pediatric Society. Management of primary nocturnal  
922 enuresis. *Paediatr Child Health*. 2005;10(10):611–4.  
923 28. Buckley BS, et al. Prevalence of urinary incontinence in  
924 men, women, and children—current evidence: findings of the  
925 fourth international consultation on incontinence. *Urology*.  
926 2010;76(2):265–70.  
927 29. Sinha R, Raut S. Management of nocturnal enuresis - myths and  
928 facts. *World J Nephrol*. 2016;5(4):328–38.  
929 30. Koff SA. Cure of nocturnal enuresis: why isn't desmopressin very  
930 effective? *Pediatr Nephrol*. 1996;10(5):667–70.  
931 31. Forsythe WI, Redmond A. Enuresis and spontaneous cure rate.  
932 Study of 1129 enuretics. *Arch Dis Child*. 1974;49(4):259–63.

- 933 32. Theunis M, et al. Self-image and performance in children with  
934 nocturnal enuresis. *Eur Urol.* 2002;41(6):660–7. 999
- 935 33. Hagglob B, et al. Self-esteem in children with nocturnal enu- 1000  
936 resis and urinary incontinence: improvement of self-esteem after 1001  
937 treatment. *Eur Urol.* 1998;33(Suppl 3):16–9. 1002
- 938 34. Kamperis K, et al. Optimizing response to desmopressin in 1003  
939 patients with monosymptomatic nocturnal enuresis. *Pediatr 1004  
940 Nephrol.* 2017;32(2):217–26. 1005
- 941 35. Nijman RJM, et al. Diagnosis and management of urinary 1006  
942 incontinence and encopresis in childhood. Committee 11, 1007  
943 Chapter 16; 2005. 1008
- 944 36. Rittig S, et al. Effect of food intake on the pharmacokinetic and 1009  
945 antidiuretic activity of oral desmopressin (DDAVP) in hydrated 1010  
946 normal subjects. *Clin Endocrinol.* 1998;48:235–41. 1011
- 947 37. Vande Walle JGJ, et al. A new fast-melting oral formulation 1012  
948 of desmopressin: a pharmacodynamic study in children with 1013  
949 primary nocturnal enuresis. *BJU Int.* 2006;97:603–9. 1014
- 950 38. De Guchtenaere A, et al. Evidence of partial anti-enuretic 1015  
951 response related to poor pharmacodynamic effects of desmo- 1016  
952 pressin nasal spray. *J Urol.* 2009;181:302–9. 1017
- 953 39. Marschall-Kehrel D, Harms TW. Structured desmopres- 1018  
954 sin withdrawal improves response and treatment outcome 1019  
955 for monosymptomatic enuretic children. *J Urol.* 2009;182(4 1020  
956 Suppl):2022–6. 1021
- 957 40. Ohtomo Y, et al. Gradual tapering of desmopressin leads to better 1022  
958 outcome in nocturnal enuresis. *Pediatr Int.* 2015;57(4):656–8. 1023
- 959 41. Chua ME, et al. Desmopressin withdrawal strategy for pediatric 1024  
960 enuresis: a meta-analysis. *Pediatrics.* 2016; 138(1). 1025
- 961 42. Dalrymple RA, Wacogne ID. Gradual withdrawal of desmo- 1026  
962 pressin in patients with enuresis leads to fewer relapses than an 1027  
963 abrupt withdrawal. *Arch Dis Child Educ Pract Ed.* 2017;102:335. 1028
- 964 43. Perrin N, Sayer L, While A. The efficacy of alarm therapy versus 1029  
965 desmopressin therapy in the treatment of primary mono-symp- 1030  
966 tomatic nocturnal enuresis: a systematic review. *Prim Health Care 1031  
967 Res Dev.* 2015;16(1):21–31. 1032
- 968 44. Peng CC, et al. Systematic review and meta-analysis of alarm 1033  
969 versus desmopressin therapy for pediatric monosymptomatic 1034  
970 enuresis. *Sci Rep.* 2018; 8(1):16755. 1035
- 971 45. Evans J, et al. Randomized comparison of long-term desmo- 1036  
972 pressin and alarm treatment for bedwetting. *J Pediatr Urol.* 1037  
973 2011;7(1):21–9. 1038
- 974 46. Önlü FF, et al. Comparison of long-term efficacy of desmopressin 1039  
975 lyophilisate and enuretic alarm for monosymptomatic enuresis 1040  
976 and assessment of predictive factors for success: a randomized 1041  
977 prospective trial. *J Urol.* 2015;193(2):655–61. 1042
- 978 47. Song P, et al. Comparison of desmopressin, alarm, desmopressin 1043  
979 plus alarm, and desmopressin plus anticholinergic agents in the 1044  
980 management of paediatric monosymptomatic nocturnal enuresis: 1045  
981 a network meta-analysis. *BJU Int.* 2019;123(3):388–400. 1046
- 982 48. Lee T, et al. Comparison of effects of treatment of primary noct- 1047  
983 urnal enuresis with oxybutynin plus desmopressin, desmopres- 1048  
984 sin alone or imipramine alone: a randomized controlled clinical 1049  
985 trial. *J Urol.* 2005;174(3):1084–7. 1050
- 986 49. Naitoh Y, et al. Combination therapy with alarm and drugs for 1051  
987 monosymptomatic nocturnal enuresis not superior to alarm 1052  
988 monotherapy. *Urology.* 2005;66(3):632–5. 1053
- 989 50. De Guchtenaere A, et al. Desmopressin resistant nocturnal poly- 1054  
990 uria may benefit from furosemide therapy administered in the 1055  
991 morning. *J Urol.* 2007;178(6):2635–9. 1056
- 992 51. Alloussi SH, et al. Failure of monotherapy in primary mono- 1057  
993 symptomatic enuresis: a combined desmopressin and propive- 1058  
994 rine treatment regimen improves efficacy outcomes. *BJU Int.* 1059  
995 2009;103(12):1706–12. 1060
- 996 52. Jabbour M, Abou Zahr R, Boustany M. Primary nocturnal enu- 1061  
997 resis: a novel therapeutic strategy with higher efficacy. *Urology.* 1062  
998 2019;124:241–7. 1063  
1064
53. Park SJ, et al. Desmopressin alone versus desmopressin and an 999  
anticholinergic in the first-line treatment of primary monosymp- 1000  
omatic nocturnal enuresis: a multicenter study. *Pediatr Nephrol.* 1001  
2014;29(7):1195–200. 1002
54. Radvanska E, Kovács L, Rittig S. The role of bladder capacity in 1003  
antidiuretic and anticholinergic treatment for nocturnal enuresis. 1004  
*J Urol* 2006;176(2):764–8 (**discussion 768–9**). 1005
55. Azarfar A, et al. Comparison of combined treatment with desmo- 1006  
pressin plus oxybutynin and desmopressin plus tolterodine in 1007  
treatment of children with primary nocturnal enuresis. *J Renal 1008  
Inj Prev.* 2015;4(3):80–6. 1009
56. Kamperis K, et al. Combination treatment of nocturnal enu- 1010  
resis with desmopressin and indomethacin. *Pediatr Nephrol.* 1011  
2017;32(4):627–33. 1012
57. Joukadar C, et al. A replicate study design for testing bioequiva- 1013  
lence: a case study on two desmopressin nasal spray preparations. 1014  
*Eur J Clin Pharmacol.* 2003;59:631–6. 1015
58. Nevés T, et al. Osmoregulation and desmopressin pharmaco- 1016  
kinetics in enuretic children. *Pediatric.* 1999;103:65–70. 1017
59. Lundin S, Vilhardt H. Absorption of 1-deamino-8-D-arginine 1018  
from different regions of the gastrointestinal tract in rabbits. *Acta 1019  
Endocrinol.* 1986;112:457–60. 1020
60. d'Agay-Abensour L, et al. Absolute bioavailability of an aqueous 1021  
solution of 1-deamino-8-D-arginine vasopressin from different 1022  
regions of the gastrointestinal tract in man. *Eur J Clin Pharmacol.* 1023  
1993;44(5):473–6. 1024
61. Fjellstad-Paulsen A, et al. Pharmacokinetics of 1-deamino-8-D- 1025  
arginine vasopressin after various routes of administration in 1026  
healthy volunteers. *Clin Endocrinol.* 1993;38:177–82. 1027
62. Michelet R, et al. Claiming desmopressin therapeutic equivalence 1028  
in children requires pediatric data: a population PKPD analysis. 1029  
*Eur J Clin Pharmacol.* 2018;74(3):297–305. 1030
63. Li X, et al. Pharmacokinetics and safety profile of desmo- 1031  
pressin oral tablet formulations in healthy Chinese subjects 1032  
under fasting and fed conditions. *Int J Clin Pharmacol Ther.* 1033  
2018;56(9):434–42. 1034
64. Callrés T, et al. Changes in gastrointestinal motility influ- 1035  
ence the absorption of desmopressin. *Eur J Clin Pharmacol.* 1036  
1999;55:305–9. 1037
65. Odeberg JM, et al. A pharmacokinetic and pharmacodynamic 1038  
study of desmopressin : evaluating sex differences and the effect 1039  
of pre-treatment of piroxicam, and further validation of an indi- 1040  
rect response model. *J Pharm Pharmacol.* 2004;56:1389–98. 1041
66. Rembratt A, et al. Pharmacokinetics and pharmacodynamics of 1042  
desmopressin administered orally versus intravenously at day- 1043  
time versus night-time in healthy men aged 55–70 years. *Eur J 1044  
Clin Pharmacol.* 2004;60:397–402. 1045
67. Sørensen PS, et al. Impermeability of the blood-cerebrospinal 1046  
fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) 1047  
in patients with acquired, communicating hydrocephalus. *Eur J 1048  
Clin Invest.* 1984;14(6):435–9. 1049
68. Burrow GN, et al. DDAVP treatment of diabetes insipidus dur- 1050  
ing pregnancy and the post-partum period. *Acta Endocrinol 1051  
(Copenh).* 1981;97(1):23–5. 1052
69. Shimizu K, et al. Antidiuretic hormone. Tokyo: University Pack 1053  
Press; 1980. 1054
70. Fjellstad-Paulsen A, Lundin S. Metabolism of vasopressin, oxy- 1055  
tocin and their analogues [Mpa1, D-Arg8]-vasopressin (dDAVP) 1056  
and [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in human 1057  
kidney and liver homogenates. *Regul Pept.* 1996;67(1):27–322. 1058
71. Lundin S, et al. Biliary excretion of the vasopressin analogue 1059  
DDAVP after intraduodenal, intrajugular and intraportal admin- 1060  
istration in the conscious pig. *Pharm Tox.* 1991;68:177–80. 1061
72. Fjellstad-Paulsen A, Söderberg-Ahlm C, Lundin S. Metabolism 1062  
of vasopressin, oxytocin, and their analogues in the human gas- 1063  
trointestinal tract. *Peptides.* 1995;16(6):1141–7. 1064



- 1065 73. Fjellstad-Paulsen A, et al. Bioavailability of 1-deamino-8-D-  
1066 arginine vasopressin with an enzyme inhibitor (aprotinin) from  
1067 the small intestine in healthy volunteers. *Eur J Clin Pharmacol.*  
1068 1996;50:491–5.
- 1069 74. Agero H, et al. Pharmacokinetics and renal excretion of desmo-  
1070 pressin after intravenous administration to healthy subjects and  
1071 renally impaired patients. *Br J Clin Pharm.* 2004;58(4):352–8.
- 1072 75. Cvetkovic RS, Plosker GL. Desmopressin in adults with nocturia.  
1073 *Drugs.* 2005;65(1):99–107.
- 1074 76. Lam KSL, et al. Pharmacokinetics, pharmacodynamics, long-  
1075 term efficacy and safety of oral 1-deamino-8-D-arginine vaso-  
1076 pressin in adult patients with central diabetes insipidus. *Br J Clin*  
1077 *Pharmacol.* 1996;42:379–85.
- 1078 77. Hvistendahl GM, et al. The pharmacokinetics of 400 µg of oral  
1079 desmopressin in elderly patients with nocturia, and the correla-  
1080 tion between the absorption of desmopressin and clinical effect.  
1081 *BJU Int.* 2004;95:804–9.
- 1082 78. Kaehler ST, et al. A bioequivalence study of two oral desmopres-  
1083 sin tablet formulations. *Pharmacology.* 2006;77:46–52.
- 1084 79. Williams TD, et al. Antidiuretic effect and pharmacokinetics of  
1085 oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults  
1086 and children. *J Clin Endocrinol Metab.* 1986;63(1):129–32.
- 1087 80. Argenti D, Ireland D, Heald DL. A pharmacokinetic and phar-  
1088 macodynamics comparison of desmopressin administered as  
1089 whole, chewed and crushed tablets, and as an oral solution. *J*  
1090 *Urol.* 2001;165:1446–511.
- 1091 81. Steiner IM, et al. Plasma pharmacokinetics of desmopressin fol-  
1092 lowing sublingual administration: an exploratory dose-escala-  
1093 tion study in healthy male volunteers. *Int J Clin Pharm Therp.*  
1094 2006;44(4):172–9.
- 1095 82. Fransén N, Bredenberg S, Björk E. Clinical study shows  
1096 improved absorption of desmopressin with novel formulation.  
1097 *Pharmaceut Res.* 2009;26(7):1618–25.
- 1098 83. Ruzicka H, et al. Pharmacokinetics and antidiuretic effect of  
1099 high-dose desmopressin in patients with chronic renal failure.  
1100 *Pharmacol Toxicol.* 2003;92(3):137–42.
- 1101 84. Järvelin MR, et al. Enuresis in seven-year-old children. *Acta Pae-  
1102 diatr Scand.* 1988;77:148–53.
- 1103 85. Hjälmås K, Bengtsson B. Efficacy, safety and dosing of desmo-  
1104 pressin for nocturnal enuresis in Europe. *Clin Pediatr (Phila)*  
1105 1993;19–24.
- 1106 86. Nørgaard J-P, et al. A pharmacodynamic study of desmopressin  
1107 in patients with nocturnal enuresis. *J Urol.* 1995;153:1984–6.
- 1108 87. Pedersen PS, Hejl M, Kjølner SS. Desamino-D-arginine vasopres-  
1109 sin in childhood nocturnal enuresis. *J Urol.* 1985;133(1):65–6.
- 1110 88. Hjälmås K, et al. Long-term treatment with desmopressin in chil-  
1111 dren with primary monosymptomatic nocturnal enuresis: an open  
1112 multicentre study. Swedish Enuresis Trial (SWEET) Group. *Br J*  
1113 *Urol.* 1998;82(5):704–9.
- 1114 89. Läckgren G, et al. Desmopressin in the treatment of severe noctur-  
1115 nal enuresis in adolescents—a 7-year follow-up study. *Br J*  
1116 *Urol.* 1998;81(Suppl 3):17–23.
- 1117 90. Hvistendahl GM, et al. The relationship between desmo-  
1118 pressin treatment and voiding pattern in children. *BJU Int.*  
1119 2002;89(9):917–22.
- 1120 91. Wolfish NM, et al. The Canadian Enuresis Study and Evaluation—  
1121 short- and long-term safety and efficacy of an oral desmopressin  
1122 preparation. *Scand J Urol Nephrol.* 2003;37(1):22–7.
- 1123 92. Lottmann H, et al. Long-term desmopressin response in primary  
1124 nocturnal enuresis: open-label, multinational study. *Int J Clin*  
1125 *Pract.* 2009;63(1):35–45.
- 1126 93. Schulz-Jürgensen S, Feldmann B, Eggert P. Desmopressin in the  
1127 treatment of enuresis: Is lyophilisate superior to tablets? *Aktuelle*  
1128 *Urol.* 2016;47(6):480–6.
94. De Guchteneere A, et al. Oral lyophilisate formulation of desmo-  
pressin: superior pharmacodynamics compared to tablet due to  
low food interaction. *J Urol.* 2011;185(6):2308–13.
95. Lottmann H, et al. A randomized comparison of oral desmopres-  
sin lyophilisate (MELT) and tablet formulations in children and  
adolescents with primary nocturnal enuresis. *Int J Clin Pract.*  
2007;61(9):1454–60.
96. Juul KV, et al. Desmopressin melt improves response and compli-  
ance compared with tablet in treatment of primary monosympto-  
matic nocturnal enuresis. *Eur J Pediatr.* 2013;172(9):1235–42.
97. Nørgaard J-P. Pathophysiology of nocturnal enuresis. *Scand J*  
*Urol Nephrol.* 1991;140:1–35.
98. Ferrara P, et al. The adverse effects of oral desmopressin lyophi-  
lisate (MELT): personal experience on enuretic children. *Turk*  
*J Urol.* 2018;44(1):51–5.
99. Glazener CMA, Evans JHC. Desmopressin for nocturnal enuresis  
in children. *Cochrane Database Syst Rev* 2002;(3):CD002112.
100. Nørgaard J-P. A clinical and pharmacological model for  
explaining response to desmopressin. *Scand J Urol Nephrol.*  
1999;202:53–5.
101. Rushton HG, et al. The influence of small functional bladder  
capacity and other predictors on the response to desmopressin  
in the management of monosymptomatic nocturnal enuresis. *J*  
*Urol.* 1996;156(2):651–5.
102. Hogg RJ, Husmann D. The role of family history in predict-  
ing response to desmopressin in nocturnal enuresis. *J Urol.*  
1993;150(2 Pt 1):444–5.
103. Schaumburg HL, Rittig S, Djurhuus JC. No relationship between  
family history of enuresis and response to desmopressin. *J Urol.*  
2001;166(6):2435–7.
104. Devitt H, et al. Plasma vasopressin and response to treatment in  
primary nocturnal enuresis. *Arch Dis Child.* 1999;80(5):448–51.
105. Kruse S, et al. Treatment of primary monosymptomatic noctur-  
nal enuresis with desmopressin: predictive factors. *BJU Int.*  
2001;88(6):572–6.
106. Van Herzele C, et al. Predictive parameters of response to  
desmopressin in primary nocturnal enuresis. *J Pediatr Urol.*  
2015;11(4):200.e1–8.
107. Van Herzele C, et al. Poor compliance with primary nocturnal  
enuresis therapy may contribute to insufficient desmopressin  
response. *J Urol.* 2009;182(4 Suppl):2045–9.
108. Juul KV, et al. Gender difference in antidiuretic response to desmo-  
pressin. *Am J Physiol Renal Physiol.* 2011;300:F116–F12222.
109. Liu J, et al. Sex differences in vasopressin V2 receptor expres-  
sion, and vasopressin-induced antidiuresis. *Am J Physiol Renal*  
*Physiol.* 2011;300:F433–F440440.
110. Carrel L, Willard HF. X-inactivation profile reveals extensive  
variability in X-linked gene expression in females. *Nature.*  
2005;434:400–4.
111. Schroeder MK, et al. Desmopressin use in pediatric nocturnal  
enuresis patients: is there a sex difference in prescription pat-  
terns? *Eur J Pediatr.* 2018;177(3):389–94.
112. Fjellstad-Paulsen A, Wille S, Harris AS. Comparison of intrana-  
sal and oral desmopressin for nocturnal enuresis. *Arch Dis Child.*  
1987;62(7):674–7.
113. Li Volti S, et al. The nasal mucosa of children with nocturnal enu-  
resis before and after treatment with 1-deamino 8-D-arginine vas-  
opressin spray. *Int J Pediatr Otorhinolaryngol.* 2001;58(3):211–4.
114. Akoğlu E, et al. Effect of 1-deamino 8-D-arginine vasopressin  
spray on nasal cytology and mucociliary clearance in patients  
with nocturnal enuresis. *Int J Pediatr Otorhinolaryngol.*  
2006;70(11):1919–22.
115. Nevés T, Bader G, Sillén U. Enuresis, sleep and desmopressin  
treatment. *Acta Paediatr.* 2002;91(10):1121–5.

- 1193 116. Dehoorne JL, et al. Desmopressin toxicity due to prolonged  
1194 half-life in 18 patients with nocturnal enuresis. *J Urol.*  
1195 2006;176(2):754–7 (**discussion 757–8**). 1210  
1196 117. Thumfart J, et al. Desmopressin associated symptomatic hypona- 1211  
1197 tremic hypervolemia in children. Are there predictive factors? *J* 1212  
1198 *Urol.* 2005;174(1):294–8 (**discussion 298**). 1213  
1199 118. Lucchini B, et al. Severe signs of hyponatremia secondary to 1214  
1200 desmopressin treatment for enuresis: a systematic review. *J Pedi-* 1215  
1201 *atr Urol.* 2013;9(6 Pt B):1049–53. 1216  
1202 119. Del Gado R, et al. Desmopressin is a safe drug for the treatment 1217  
1203 of enuresis. *Scand J Urol Nephrol.* 2005;39(4):308–12. 1218  
1204 120. Kano K, Arisaka O. Efficacy and safety of nasal desmopressin in 1219  
1205 the long-term treatment of primary nocturnal enuresis. *Pediatr* 1220  
1206 *Nephrol.* 2006;21(8):1211. 1221  
1207 121. Knudsen UB, et al. Long-term treatment of nocturnal enu- 1222  
1208 resis with desmopressin. A follow-up study. *Urol Res.* 1223  
1209 1991;19(4):237–40. 1224  
1225
122. Alloussi SH, et al. Desmopressin treatment regimens in mono- 1210  
symptomatic and nonmonosymptomatic enuresis: A review from 1211  
a clinical perspective. *J Pediatr Urol.* 2011;7(1):10–20. 1212  
123. Donoghue MB, et al. Hyponatremic seizure in a child using 1213  
desmopressin for nocturnal enuresis. *Arch Pediatr Adolesc Med.* 1214  
1998;152(3):290–2. 1215  
124. Beach PS, Beach RE, Smith LR. Hyponatremic seizures in a 1216  
child treated with desmopressin to control enuresis. A rational 1217  
approach to fluid intake. *Clin Pediatr (Phila)* 1992;31(9):566–9. 1218  
125. Boetzkes S, et al. Two unusual pediatric cases of dilutional 1219  
hyponatremia. *Pediatr Emerg Care.* 2010;26(7):503–5. 1220  
126. Van Herzeele C, et al. Safety profile of desmopressin tablet for 1221  
enuresis in a prospective study. *Adv Ther.* 2014;31(12):1306–16. 1222  
127. Ferrara P, et al. Desmopressin 120 mcg, 180 mcg, 240 mcg: 1223  
the right treatment for the right patient. *Arch Ital Urol Androl.* 1224  
2018;90(2):127–9. 1225

## Affiliations

Elke Gasthuys<sup>1,2,3,4</sup>  · Lien Dossche<sup>1</sup> · Robin Michelet<sup>3</sup> · Jens Peter Nørgaard<sup>1</sup> · Mathias Devreese<sup>5</sup> · Siska Croubels<sup>5</sup> · An Vermeulen<sup>4</sup> · Jan Van Bocxlaer<sup>4</sup> · Johan Vande Walle<sup>1</sup>

<sup>1</sup> Department of Pediatric Nephrology, Faculty of Medicine and Health Sciences, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium

<sup>2</sup> Health, Innovation and Research Institute, Faculty of Medicine and Health Sciences, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium

<sup>3</sup> Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Kelchstr. 31, 12169 Berlin, Germany

<sup>4</sup> Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium

<sup>5</sup> Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium

Journal:	<b>40272</b>
Article:	<b>401</b>

## Author Query Form

**Please ensure you fill out your response to the queries raised below and return this form along with your corrections**

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the 'Author's response' area provided below

Query	Details Required	Author's Response
AQ1	Kindly check and confirm that the given and family name of these authors "Jens Peter Nørgaard, Johan Vande Walle" are correctly identified.	
AQ2	Kindly check and provide the complete details for these references [35, 41, 85, 99].	

Author Proof